- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Mickie Henshall
Independent Director
Mickie Henshall is the Chief Business Officer at Ambry Genetics, where she leads commercial operations, product management, marketing, and market access. With over 20 years of experience, Mickie has driven commercial success for high-growth diagnostic and life sciences companies, from startups to Fortune 1000 organizations. Her expertise includes portfolio development, commercial strategy, revenue generation and brand building.
Prior to her current role, she held leadership positions at REALM IDx, Genomic Life, Agena Bioscience, Accriva Diagnostics, Biotix and Illumina.
Mickie is recognized for her strategic vision and global market experience, having led regional teams in Europe, China and Australia.
“There is enormous potential for Volition to revolutionize the diagnosis of life-altering diseases through its Nu.Q® product portfolio. I look forward to supporting the board and senior leadership team in realizing Volition’s mission.”
Mickie Henshall
Independent Director